TriangleDC/AML Fusion Vaccine (NCT07374029)
DC/AML Fusion Vaccine trial for Acute Myeloid Leukemia (NCT07374029). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for acute myeloid leukemia, in patients treated with decitabine and venetoclax.
The idea: add personalized immune cells. A vaccine is made by fusing a patient's dendritic cells with their own leukemia cells. T cells stimulated by that fusion are collected, grown, and given back by vein.
This is the first time these primed T cells will be given to people. The study asks about feasibility and safety. At Beth Israel Deaconess in Boston, David Avigan leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.